How I reduce and treat posttransplant relapse of MDS

3.

Bernard

E

,

Tuechler

H

,

Greenberg

PL

, et al.

Molecular international prognostic scoring system for myelodysplastic syndromes

.

NEJM Evidence

.

2022

;

1

(

7

):

EVIDoa2200008

.

4.

Papaemmanuil

E

,

Gerstung

M

,

Malcovati

L

, et al.

Clinical and biological implications of driver mutations in myelodysplastic syndromes

.

Blood

.

2013

;

122

(

22

):

3616

-

3699

.

5.

Sallman

DA

,

Tanaka

TN

,

List

A

,

Bejar

R

.

SOHO state of the art update and next questions: biology and treatment of myelodysplastic syndromes

.

Clin Lymphoma Myeloma Leuk

.

2017

;

17

(

10

):

613

-

620

.

6.

Greenberg

P

,

Cox

C

,

LeBeau

MM

, et al.

International scoring system for evaluating prognosis in myelodysplastic syndromes

.

Blood

.

1997

;

89

(

6

):

2079

-

2088

.

7.

Malcovati

L

,

Germing

U

,

Kuendgen

A

, et al.

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

.

J Clin Oncol

.

2007

;

25

(

23

):

3503

-

3510

.

8.

Greenberg

PL

,

Tuechler

H

,

Schanz

J

, et al.

Revised international prognostic scoring system for myelodysplastic syndromes

.

Blood

.

2012

;

120

(

12

):

2454

-

2465

.

9.

Fenaux

P

,

Mufti

GJ

,

Hellstrom-Lindberg

E

, et al.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

.

Lancet Oncol

.

2009

;

10

(

3

):

223

-

232

.

10.

Kantarjian

HM

,

Thomas

XG

,

Dmoszynska

A

, et al.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

.

J Clin Oncol

.

2012

;

30

(

21

):

2670

-

2677

.

11.

Merlevede

J

,

Droin

N

,

Qin

T

, et al.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

.

Nat Commun

.

2016

;

7

:

10767

.

12.

Craddock

C

,

Quek

L

,

Goardon

N

, et al.

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

.

Leukemia

.

2013

;

27

(

5

):

1028

-

1036

.

13.

Nakamura

R

,

Saber

W

,

Martens

MJ

, et al.

Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome

.

J Clin Oncol

.

2021

;

39

(

30

):

3328

-

3339

.

14.

Kröger

N

,

Sockel

K

,

Wolschke

C

, et al.

Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)

.

J Clin Oncol

.

2021

;

39

(

30

):

3318

-

3327

.

15.

Lim

Z

,

Brand

R

,

Martino

R

, et al.

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

.

J Clin Oncol

.

2010

;

28

(

3

):

405

-

411

.

16.

McClune

BL

,

Weisdorf

DJ

,

Pedersen

TL

, et al.

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

.

J Clin Oncol

.

2010

;

28

(

11

):

1878

-

1887

.

17.

Penack

O

,

Peczynski

C

,

Mohty

M

, et al.

How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT

.

Blood Adv

.

2020

;

4

(

24

):

6283

-

6290

.

18.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

19.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

20.

Della Porta

MG

,

Jackson

CH

,

Alessandrino

EP

, et al.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System

.

Leukemia

.

2017

;

31

(

11

):

2449

-

2457

.

21.

Koreth

J

,

Pidala

J

,

Perez

WS

, et al.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

.

J Clin Oncol

.

2013

;

31

(

21

):

2662

-

2670

.

22.

Yoshizato

T

,

Nannya

Y

,

Atsuta

Y

, et al.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

.

Blood

.

2017

;

129

(

17

):

2347

-

2358

.

23.

Della Porta

MG

,

Gallì

A

,

Bacigalupo

A

, et al.

Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation

.

J Clin Oncol

.

2016

;

34

(

30

):

3627

-

3637

.

24.

Bejar

R

,

Stevenson

KE

,

Caughey

B

, et al.

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

.

J Clin Oncol

.

2014

;

32

(

25

):

2691

-

2698

.

25.

Ciurea

SO

,

Chilkulwar

A

,

Saliba

RM

, et al.

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations

.

Blood

.

2018

;

131

(

26

):

2989

-

2992

.

26.

Gurnari

C

,

Robin

M

,

Godley

LA

, et al.

Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT

.

Lancet Haematol

.

2023

;

10

(

12

):

e994

-

1005

.

27.

de Witte

T

,

Bowen

D

,

Robin

M

, et al.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

.

Blood

.

2017

;

129

(

13

):

1753

-

1762

.

28.

National Comprehensive Cancer Network. MDS (Version 1.2023)

. Accessed 29 December 2023. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf.

29.

Pease

DF

,

Ross

JA

,

Poynter

JN

, et al.

Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients

.

Cancer Epidemiol

.

2015

;

39

(

2

):

222

-

228

.

30.

Muffly

LS

,

Kocherginsky

M

,

Stock

W

, et al.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

.

Haematologica

.

2014

;

99

(

8

):

1373

-

1379

.

31.

Polverelli

N

,

Tura

P

,

Battipaglia

G

, et al.

Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French–Italian 10-year experience on 228 patients

.

Bone Marrow Transplant

.

2020

;

55

(

12

):

2224

-

2233

.

32.

Malagola

M

,

Polverelli

N

,

Rubini

V

, et al.

GITMO registry study on allogeneic transplantation in patients aged ≥60 years from 2000 to 2017: improvements and criticisms

.

Transplant Cell Ther

.

2022

;

28

(

2

):

96.e1

-

96.e11

.

33.

Della Porta

MG

,

Alessandrino

EP

,

Bacigalupo

A

, et al.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

.

Blood

.

2014

;

123

(

15

):

2333

-

2342

.

34.

Shaffer

BC

,

Ahn

KW

,

Hu

ZH

, et al.

Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

.

J Clin Oncol

.

2016

;

34

(

16

):

1864

-

1871

.

35.

Gagelmann

N

,

Eikema

DJ

,

Stelljes

M

, et al.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

.

Haematologica

.

2019

;

104

(

5

):

929

-

936

.

36.

Platzbecker

U

.

Treatment of MDS

.

Blood

.

2019

;

133

(

10

):

1096

-

1107

.

37.

Robin

M

,

Porcher

R

,

Adès

L

, et al.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

.

Leukemia

.

2015

;

29

(

7

):

1496

-

1501

.

38.

Nakai

K

,

Kanda

Y

,

Fukuhara

S

, et al.

Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome

.

Leukemia

.

2005

;

19

(

3

):

396

-

401

.

39.

Alessandrino

EP

,

Della Porta

MG

,

Bacigalupo

A

, et al.

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

.

Blood

.

2008

;

112

(

3

):

895

-

902

.

40.

Garcia

JS

,

Platzbecker

U

,

Odenike

O

, et al.

Efficacy and safety of venetoclax in combination with azacitidine for the treatment of patients with treatment-naive, higher-risk myelodysplastic syndromes

.

Blood

.

2023

;

142

(

suppl 1

):

319-319

.

41.

Damaj

G

,

Duhamel

A

,

Robin

M

, et al.

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

.

J Clin Oncol

.

2012

;

30

(

36

):

4533

-

4540

.

42.

Gerds

AT

,

Gooley

TA

,

Estey

EH

,

Appelbaum

FR

,

Deeg

HJ

,

Scott

BL

.

Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS

.

Biol Blood Marrow Transplant

.

2012

;

18

(

8

):

1211

-

1218

.

43.

Lin

RJ

,

Artz

AS

.

Allogeneic hematopoietic cell transplantation for older patients

.

Hematology

.

2021

;

2021

(

1

):

254

-

263

.

44.

Heuser

M

,

Freeman

SD

,

Ossenkoppele

GJ

, et al.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

.

Blood

.

2021

;

138

(

26

):

2753

-

2767

.

45.

Zeidan

AM

,

Platzbecker

U

,

Bewersdorf

JP

, et al.

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

.

Blood

.

2023

;

141

(

17

):

2047

-

2061

.

46.

Robinson

TM

,

Bowman

RL

,

Persaud

S

, et al.

Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

.

Sci Adv

.

2023

;

9

(

38

):

eadg0488

.

47.

Nakamura

S

,

Yokoyama

K

,

Shimizu

E

, et al.

Prognostic impact of circulating tumor DNA status post–allogeneic hematopoietic stem cell transplantation in AML and MDS

.

Blood

.

2019

;

133

(

25

):

2682

-

2695

.

48.

Lindsley

RC

,

Saber

W

,

Mar

BG

, et al.

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation

.

N Engl J Med

.

2017

;

376

(

6

):

536

-

547

.

49.

Ma

Y

,

Wei

Z

,

Xu

Y

, et al.

Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: a multicenter, retrospective cohort study

.

Cancer

.

2023

;

129

(

13

):

2013

-

2022

.

50.

Festuccia

M

,

Deeg

HJ

,

Gooley

TA

, et al.

Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome

.

Biol Blood Marrow Transplant

.

2016

;

22

(

7

):

1227

-

1233

.

51.

Dillon

LW

,

Gui

G

,

Logan

BR

, et al.

Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome

.

JCO Precis Oncol

.

2021

;

5

:

265

-

274

.

52.

SCHULZ

E

,

Aplan

PD

,

Freeman

SD

,

Pavletic

SZ

.

Towards a conceptualization of measurable residual disease in myelodysplastic syndromes

.

Blood Adv

.

2023

;

7

(

16

):

4381

-

4394

.

53.

Malagola

M

,

Polverelli

N

,

Beghin

A

, et al.

Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia

.

Front Oncol

.

2023

;

13

:

1133418

.

54.

Scott

BL

,

Pasquini

MC

,

Fei

M

, et al.

Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial

.

Transplant Cell Ther

.

2021

;

27

(

6

):

483.e1

-

483.e6

.

55.

Kröger

N

,

Iacobelli

S

,

Franke

GN

, et al.

Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial)

.

J Clin Oncol

.

2017

;

35

(

19

):

2157

-

2164

.

56.

Oran

B

,

Woo Ahn

K

,

Fretham

C

, et al.

Fludarabine and melphalan compared with reduced doses of busulfan and flurabine improves transplant outcomes in older MDS patients

.

Blood

.

2019

;

134

(

suppl 1

):

253-253

.

57.

Spyridonidis

A

,

Labopin

M

,

Savani

BN

, et al.

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

.

Bone Marrow Transplant

.

2020

;

55

(

6

):

1114

-

1125

.

58.

Luznik

L

,

O’Donnell

PV

,

Symons

HJ

, et al.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2008

;

14

(

6

):

641

-

650

.

59.

Besse

K

,

Maiers

M

,

Confer

D

,

Albrecht

M

.

On modeling human leukocyte antigen–identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source

.

Biol Blood Marrow Transplant

.

2016

;

22

(

3

):

410

-

417

.

60.

Guru Murthy

GS

,

Kim

S

,

Hu

ZH

, et al.

Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors

.

JAMA Oncol

.

2022

;

8

(

3

):

404

-

411

.

61.

Kröger

N

,

Zabelina

T

,

de Wreede

L

, et al.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

.

Leukemia

.

2013

;

27

(

3

):

604

-

609

.

62.

Barker

JN

,

Boughan

K

,

Dahi

PB

, et al.

Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis

.

Blood Adv

.

2019

;

3

(

7

):

939

-

944

.

63.

Saber

W

,

Cutler

CS

,

Nakamura

R

, et al.

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

.

Blood

.

2013

;

122

(

11

):

1974

-

1982

.

64.

Maurer

K

,

Ho

VT

,

Inyang

E

, et al.

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD

.

Blood Adv

.

2023

;

7

(

15

):

3903

-

3915

.

65.

Grunwald

MR

,

Zhang

MJ

,

Elmariah

H

, et al.

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

.

Blood Adv

.

2021

;

5

(

4

):

975

-

983

.

66.

Robin

M

,

Porcher

R

,

Ruggeri

A

, et al.

HLA-mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis

.

Biol Blood Marrow Transplant

.

2019

;

25

(

1

):

114

-

120

.

67.

Piemontese

S

,

Boumendil

A

,

Labopin

M

, et al.

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT

.

J Hematol Oncol

.

2019

;

12

(

1

):

68

.

68.

DeFilipp

Z

,

Ciurea

SO

,

Cutler

C

, et al.

Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

.

Transplant Cell Ther

.

2023

;

29

(

2

):

71

-

81

.

69.

Gerds

AT

,

Woo Ahn

K

,

Hu

ZH

, et al.

Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes

.

Biol Blood Marrow Transplant

.

2017

;

23

(

6

):

971

-

979

.

70.

Kekre

N

,

Kim

HT

,

Thanarajasingam

G

, et al.

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

.

Haematologica

.

2015

;

100

(

9

):

1222

-

1227

.

71.

Oran

B

,

Giralt

S

,

Couriel

D

, et al.

Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

.

Leukemia

.

2007

;

21

(

12

):

2540

-

2544

.

72.

Kolb

HJ

,

Mittermüller

J

,

Clemm

C

, et al.

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

.

Blood

.

1990

;

76

(

12

):

2462

-

2465

.

73.

Motabi

IH

,

Ghobadi

A

,

Liu

J

, et al.

Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant

.

Biol Blood Marrow Transplant

.

2016

;

22

(

7

):

1324

-

1329

.

74.

Bachireddy

P

,

Hainz

U

,

Rooney

M

, et al.

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion

.

Blood

.

2014

;

123

(

9

):

1412

-

1421

.

75.

Deol

A

,

Lum

LG

.

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

.

Cancer Treat Rev

.

2010

;

36

(

7

):

528

-

538

.

76.

Orti

G

,

Barba

P

,

Fox

L

,

Salamero

O

,

Bosch

F

,

Valcarcel

D

.

Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect

.

Exp Hematol

.

2017

;

48

:

1

-

11

.

77.

Yan

CH

,

Liu

DH

,

Liu

KY

, et al.

Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

.

Blood

.

2012

;

119

(

14

):

3256

-

3262

.

78.

Krishnamurthy

P

,

Potter

VT

,

Barber

LD

, et al.

Outcome of donor lymphocyte infusion after T cell–depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes

.

Biol Blood Marrow Transplant

.

2013

;

19

(

4

):

562

-

568

.

79.

Deol

A

,

Lum

LG

.

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

.

Cancer Treat Rev

.

2010

;

36

(

7

):

528

-

538

.

80.

Collins

RH

,

Shpilberg

O

,

Drobyski

WR

, et al.

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

.

J Clin Oncol

.

1997

;

15

(

2

):

433

-

444

.

81.

Middeke

JM

,

Herbst

R

,

Parmentier

S

, et al.

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

.

Leukemia

.

2016

;

30

(

2

):

261

-

267

.

82.

Zuanelli Brambilla

C

,

Lobaugh

SM

,

Ruiz

JD

, et al.

Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy

.

Transplant Cell Ther

.

2021

;

27

(

9

):

771.e1

-

771.e10

.

83.

Shimomura

Y

,

Hara

M

,

Tachibana

T

, et al.

Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome

.

Br J Haematol

.

2019

;

186

(

1

):

86

-

90

.

84.

Schmid

C

,

de Wreede

LC

,

van Biezen

A

, et al.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

.

Haematologica

.

2018

;

103

(

2

):

237

-

245

.

85.

Kernan

NA

,

Grupp

S

,

Smith

AR

, et al.

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome

.

Br J Haematol

.

2018

;

181

(

6

):

816

-

827

.

86.

Coppell

JA

,

Richardson

PG

,

Soiffer

R

, et al.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

.

Biol Blood Marrow Transplant

.

2010

;

16

(

2

):

157

-

168

.

87.

Khimani

F

,

McDonald

GB

,

Shulman

HM

, et al.

Hepatic veno-occlusive disease following sirolimus-based immune suppression

.

Bone Marrow Transplant

.

2019

;

54

(

1

):

85

-

89

.

88.

Corbacioglu

S

,

Jabbour

EJ

,

Mohty

M

.

Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome

.

Biol Blood Marrow Transplant

.

2019

;

25

(

7

):

1271

-

1280

.

89.

Carreras

E

,

Bertz

H

,

Arcese

W

, et al.

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party

.

Blood

.

1998

;

92

(

10

):

3599

-

3604

.

90.

Carreras

E

,

Díaz-Beyá

M

,

Rosiñol

L

,

Martínez

C

,

Fernández-Avilés

F

,

Rovira

M

.

The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade

.

Biol Blood Marrow Transplant

.

2011

;

17

(

11

):

1713

-

1720

.

91.

Imus

PH

,

Blackford

AL

,

Bettinotti

M

, et al.

Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation

.

Biol Blood Marrow Transplant

.

2017

;

23

(

11

):

1887

-

1894

.

92.

Christopeit

M

,

Kuss

O

,

Finke

J

, et al.

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change

.

J Clin Oncol

.

2013

;

31

(

26

):

3259

-

3271

.

93.

Dinardo

C

,

Roboz

G

,

M Watts

J

, et al.

P724: updated substudy results for ivosidenib in IDH1-mutant relapsed/refractory myelodysplastic syndrome

.

Hemasphere

.

2023

;

7

(

S3

):

e75740ab

.

94.

Stein

EM

,

DiNardo

CD

,

Fathi

AT

, et al.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

.

Blood

.

2019

;

133

(

7

):

676

-

687

.

95.

Ades

L

,

Dimicoli-Salazar

S

,

Sebert

M

, et al.

Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the Ideal phase 2 study by the GFM Group

.

Blood

.

2021

;

138

(

suppl 1

):

63

.

96.

Venugopal

S

,

Dinardo

CD

,

Takahashi

K

, et al.

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS)

.

J Clin Oncol

.

2021

;

39

(

suppl 15

):

7010

.

97.

Sebert

M

,

Cluzeau

T

,

Beyne Rauzy

O

, et al.

Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM Group

.

Blood

.

2021

;

138

(

suppl 1

):

62

.

98.

Bains

A

,

Luthra

R

,

Medeiros

LJ

,

Zuo

Z

.

FLT3 and NPM1 mutations in myelodysplastic syndromes

.

Am J Clin Pathol

.

2011

;

135

(

1

):

62

-

69

.

99.

Richard-Carpentier

G

,

DeZern

AE

,

Takahashi

K

, et al.

Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS)

.

Blood

.

2019

;

134

(

suppl 1

):

678-678

.

100.

Ades

L

,

Dimicoli-Salazar

S

,

Sebert

M

, et al.

Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS) : the ideal phase 2 study by the GFM group

.

Blood

.

2021

;

138

(

suppl 1

):

63

. 63.

101.

Pang

WW

,

Czechowicz

A

,

Logan

AC

, et al.

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice

.

Blood

.

2019

;

133

(

19

):

2069

-

2078

.

102.

Luznik

L

,

Bolaños-Meade

J

,

Zahurak

M

, et al.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

.

Blood

.

2010

;

115

(

16

):

3224

-

3230

.

103.

Mielcarek

M

,

Furlong

T

,

O’Donnell

P V

, et al.

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

.

Blood

.

2016

;

127

(

11

):

1502

-

1508

.

104.

Al Malki

MM

,

Tsai

NC

,

Palmer

J

, et al.

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

.

Blood Adv

.

2021

;

5

(

12

):

2650

-

2659

.

105.

Valcárcel

D

,

Martino

R

,

Caballero

D

, et al.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival

.

J Clin Oncol

.

2008

;

26

(

4

):

577

-

584

.

106.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

107.

Chang

YJ

,

Wu

DP

,

Lai

YR

, et al.

Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study

.

J Clin Oncol

.

2020

;

38

(

29

):

3367

-

3376

.

108.

Yang

X

,

Li

D

,

Xie

Y

.

Anti-thymocyte globulin prophylaxis in patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation: an updated meta-analysis

.

Front Oncol

.

2021

;

11

:

11

.

109.

Dulery

R

,

Malard

F

,

Brissot

E

, et al.

Reduced post-transplant cyclophosphamide dose associated with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation

.

Blood

.

2022

;

140

(

suppl 1

):

10517

-

10518

.

110.

DeFilipp

Z

,

Chen

YB

.

How I treat with maintenance therapy after allogeneic HCT

.

Blood

.

2023

;

141

(

1

):

39

-

48

.

111.

Dholaria

B

,

Savani

BN

,

Hamilton

BK

, et al.

Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy

.

Transplant Cell Ther

.

2021

;

27

(

1

):

6

-

20

.

112.

Oran

B

,

de Lima

M

,

Garcia-Manero

G

, et al.

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

.

Blood Adv

.

2020

;

4

(

21

):

5580

-

5588

.

113.

de Lima

M

,

Oran

B

,

Champlin

RE

, et al.

CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes

.

Biol Blood Marrow Transplant

.

2018

;

24

(

10

):

2017

-

2024

.

114.

Stevens

BM

,

Zhang

W

,

Pollyea

DA

, et al.

CD123 CAR T cells for the treatment of myelodysplastic syndrome

.

Exp Hematol

.

2019

;

74

:

52

-

63.e3

.

115.

Chapuis

AG

,

Egan

DN

,

Bar

M

, et al.

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

.

Nat Med

.

2019

;

25

(

7

):

1064

-

1072

.

116.

Huang

XJ

,

Liu

DH

,

Liu

KY

, et al.

Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia

.

J Clin Immunol

.

2008

;

28

(

3

):

276

-

283

.

117.

Gao

XN

,

Lin

J

,

Wang

SH

, et al.

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies

.

Ann Hematol

.

2019

;

98

(

1

):

185

-

193

.

118.

Von Dem Borne

PA

,

Snijders

TJF

,

van Lammeren

D

, et al.

Prophylactic donor lymphocyte infusion in patients after allogeneic stem cell transplantation with post-transplant cyclophosphamide is associated with low relapse risk and excellent survival in patients below 65 years with acute myeloid leukemia and high-risk myelodysplasia

.

Blood

.

2022

;

140

(

suppl 1

):

7742

-

7743

.

119.

Estey

E

,

Hasserjian

RP

,

Döhner

H

.

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

.

Blood

.

2022

;

139

(

3

):

323

-

332

.